Skip to main content

Table 1 Baseline and end of study characteristics of the study population

From: Major reduction of malaria morbidity with combined vitamin A and zinc supplementation in young children in Burkina Faso: a randomized double blind trial

  Baseline End of study
  Placebo (n = 74) Supplemented (n = 74) p-value Placebo (n = 74) Supplemented (n = 74) p-value
Age (months) 35.2 ± 20 37.9 ± 20 0.72 - - -
Sex       -
Female 45.9% 48.6% 0.74 - - -
Antecedent       
Reported children with fever episode on the previous year 78.30 (69–87.6) 89.20 (82.1–96.3) 0.041 - - -
Reported children with mosquito-net use on the previous night 52.7 (41.4–64.0) 56.7 (45.4–68.0) 0.62 - - -
Anthropometry       
Weight-for-height Z- score <-2.0 -0.73 ± 2.8 -0.82 ± 1.4 0.58 -1.10 ± 2 -1.03 ± 1.3 0.80
Height-for-age Z- score <-2.0 -1.60 ± 2.3 -1.50 ± 2.0 0.77 -1.5 ± 2.4 -1.49 ± 1.7 0.97
Weight-for-height Z- score <-2.0 (%) 20.3 (11.2–29.4) 13.5 (5.7–21.3) 0.20 27.0 (17.0–37.0) 23.0 (13.5–32.5) 0.56
Height-for-age Z- score <-2.0 (%) 47.3 (36.0–58.6) 40.5 (29.3–51.7) 0.40 46.0 (34.7–57.3) 35.0 (24.2–45.8) 0.20
Hematology       
Mean (SD) hemoglobin (g/dl) 9.4 ± 1.6 9.31 ± 2.3 0.75 10.21 ± 1.82 10.09 ± 1.97 0.70
Anemia ≤ 7.0 g/dl (%) 5.4 (0.4–10.5) 18.0 (9.3–26.7) 0.020 5.4 (0.4–10.5) 5.4 (0.4–10.5) 0.71
Malariometric indices       
Positive P. falciparum 61.0 (51–72) 76.0 (66.-85) 0.052 57.5% (46.2–68.8) 42.0% (32.8–55.2) 0.048
Geometric mean density P. falciparum positive asexual forms/μl 1444 (923–2259) 1589 (1026–2459) 0.38 1945 (1155–3275) 1011 (647–1579) 0.85
Enlarged spleen 61.0% (51–72) 58.0% (47–69) 0.73 57.0% (46–68) 53.0% (42–64) 0.62
  1. Mean ± SD or % (CI 95%)
  2. p < 0.05